572 related articles for article (PubMed ID: 20671116)
1. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
2. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
[TBL] [Abstract][Full Text] [Related]
3. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
Votavova P; Tomala J; Kovar M
Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
[TBL] [Abstract][Full Text] [Related]
4. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
[TBL] [Abstract][Full Text] [Related]
5. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation.
Ota N; Takase M; Uchiyama H; Olsen SK; Kanagawa O
J Immunol; 2010 Nov; 185(10):6041-8. PubMed ID: 20926799
[TBL] [Abstract][Full Text] [Related]
6. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
[TBL] [Abstract][Full Text] [Related]
7. IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.
Chenoweth MJ; Mian MF; Barra NG; Alain T; Sonenberg N; Bramson J; Lichty BD; Richards CD; Ma A; Ashkar AA
J Immunol; 2012 May; 188(9):4149-57. PubMed ID: 22447977
[TBL] [Abstract][Full Text] [Related]
8. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.
Elpek KG; Rubinstein MP; Bellemare-Pelletier A; Goldrath AW; Turley SJ
Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21647-52. PubMed ID: 21098276
[TBL] [Abstract][Full Text] [Related]
9. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
10. IFN-α primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity.
Hansen ML; Woetmann A; Krejsgaard T; Kopp KL; Søkilde R; Litman T; Straten PT; Geisler C; Wasik MA; Odum N; Eriksen KW
Mol Immunol; 2011 Sep; 48(15-16):2087-93. PubMed ID: 21813181
[TBL] [Abstract][Full Text] [Related]
11. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets.
Mortier E; Advincula R; Kim L; Chmura S; Barrera J; Reizis B; Malynn BA; Ma A
Immunity; 2009 Nov; 31(5):811-22. PubMed ID: 19913445
[TBL] [Abstract][Full Text] [Related]
12. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
13. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
14. Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells.
Falco M; Marcenaro E; Romeo E; Bellora F; Marras D; Vély F; Ferracci G; Moretta L; Moretta A; Bottino C
Eur J Immunol; 2004 Jun; 34(6):1663-72. PubMed ID: 15162436
[TBL] [Abstract][Full Text] [Related]
15. Different NK cell developmental events require different levels of IL-15 trans-presentation.
Lee GA; Liou YH; Wang SW; Ko KL; Jiang ST; Liao NS
J Immunol; 2011 Aug; 187(3):1212-21. PubMed ID: 21715685
[TBL] [Abstract][Full Text] [Related]
16. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
17. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation.
Jin GH; Hirano T; Murakami M
Int Immunol; 2008 Jun; 20(6):783-9. PubMed ID: 18448458
[TBL] [Abstract][Full Text] [Related]
19. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact.
Heiskala M; Ståhls A; Seppälä I; Timonen T
Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835
[TBL] [Abstract][Full Text] [Related]
20. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
